Evogene Stock Price, News & Analysis

Biomica, a biopharmaceutical company focused on microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced that CEO Dr. Elran Haber will present at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The presentation will highlight Biomica's innovative approaches using a Computational Predictive Biology platform to develop therapies targeting antibiotic-resistant bacteria and gastrointestinal disorders. One-on-one meetings will be available for further discussions during the summit.

Biomica Ltd., a subsidiary of Evogene (NASDAQ: EVGN), announced positive pre-clinical results for its live biotherapeutic product BMC128 in a melanoma model. The study showed that combining BMC128 with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity, achieving a 13% Objective Response Rate and doubling tumor growth inhibition compared to ICI alone. These findings support BMC128's potential in treating solid tumors and follow earlier positive results in breast cancer models. Biomica is progressing towards a first-in-human clinical trial expected later this year.

Evogene Ltd. (NASDAQ: EVGN) announced plans to host virtual investor and analyst days on April 19 and April 21, 2021, in Hebrew and English, respectively. The events will feature key presentations from CEO Ofer Haviv and the CEOs of Evogene’s subsidiaries, including Biomica and Lavie Bio, followed by Q&A sessions. The Hebrew event is scheduled for April 19 at 4 PM IST, while the English event is set for April 21 at the same time. Registration links for both webinars are provided, emphasizing Evogene's focus on computational biology for product discovery in human health and agriculture.

Evogene Ltd. (NASDAQ: EVGN) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2020, with the SEC. The report includes audited consolidated financial statements and is accessible on the SEC's website and Evogene's investor relations page. The company focuses on computational biology to advance product discovery in multiple life sciences, including human health and agriculture, utilizing its Computational Predictive Biology (CPB) platform. Shareholders can request a hard copy of the report.

Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), has signed agreements with Tikun Olam-Cannbit Pharmaceuticals Ltd. for the production and distribution of its medical cannabis products in Israel. The initial product launch is planned for next year, with an estimated market value of $260 million from approximately 80,000 active patients in Israel as of 2020. The agreements span two years or the processing of 700kg of raw material, aiming to leverage Tikun Olam-Cannbit's expertise in the medical cannabis sector.

On March 17, 2021, Plastomics and Evogene Ltd. (NASDAQ: EVGN) announced a collaboration to develop novel insect control traits for soybeans. Utilizing Plastomics' innovative chloroplast transformation technology, the partnership aims to introduce new modes of action (MoAs) insect control genes discovered through Evogene's GeneRator AI engine. With the biotech seed market projected to reach US$45 Billion by 2027, this collaboration targets the growing challenge of insect resistance in agriculture. The initiative strives to provide sustainable and effective solutions for soybean growers.

Plastomics and Evogene Ltd. (NASDAQ: EVGN) announced a collaboration to develop novel insect control traits for soybeans. Utilizing Plastomics' transformative chloroplast technology, Evogene's insect control genes will be introduced into soybeans to combat insect resistance. The global biotech seed market is projected to reach US$45 Billion by 2027, with soybean traits expected to grow at a 6.7% annual rate. This partnership aims to deliver innovative solutions to soybean growers, leveraging artificial intelligence and advanced gene delivery methods.

Evogene Ltd. (NASDAQ: EVGN) announced its financial results for 2020, highlighting a cash position of approximately $48.2 million by year-end. The company reported a consolidated net cash usage of $19.3 million for the year, with expectations of increased usage in 2021-2022 as subsidiaries progress in product development. The operating loss for 2020 was $24.8 million, up from $21.2 million in 2019. Despite increased expenses, Evogene is optimistic about its subsidiaries' advancements, particularly in immuno-oncology and herbicides, aiming for commercialization milestones in the near future.

On February 24, 2021, Cannbit Ltd. and Canonic Ltd., both leaders in the medical cannabis sector, announced a collaboration to develop novel cannabis products. The partnership aims to leverage Cannbit's extensive clinical data and Canonic's advanced computational biology platform to address key challenges in the cannabis industry. Each company will retain full commercial rights to the products developed, with cross-royalties in place. Financial terms were not disclosed, but both companies expressed optimism about the competitive advantage this collaboration could provide.